# The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

> **NCT05849246** · PHASE2 · TERMINATED · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.** · enrollment: 4 (actual)

## Conditions studied

- Non-squamous Non-small-cell Lung Cancer

## Interventions

- **DRUG:** Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
- **DRUG:** Sintilimab+Carboplatin or Cisplatin+Pemetrexed
- **DRUG:** Tusamitamab ravtansine+Sintilimab

## Key facts

- **NCT ID:** NCT05849246
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-07-31
- **Primary completion:** 2023-11-30
- **Final completion:** 2023-12-22
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** strategy terminates development, the decision is not due to any safety-related issues
- **Last updated:** 2024-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05849246

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05849246, "The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05849246. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*